A Mitchell Phelps PhD

A Mitchell Phelps PhD
Asst ProfessorCollege of Pharmacyphelps.32@osu.edu
230 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:614-688-4370Fax:
  • Leukemia Research

Research Description

Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

Current Publications

  • Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJOSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.Blood in press 10/7/2014
  • Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA, Maddocks K, Ruppert AS, Browning R, Jones J, Flynn JA dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.Leuk Res 38 1025-9 9/1/2014
  • Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MAQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.J Pharm Biomed Anal 98 160-5 9/1/2014
  • Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MAErlotinib in african americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Clin Pharmacol Ther 96 182-91 8/1/2014
  • Phelps MA, Sparreboom AIrinotecan pharmacogenetics: a finished puzzle?J Clin Oncol 32 2287-9 8/1/2014
  • Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MATumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.Leukemia in press 6/20/2014
  • Phelps MA, Sparreboom AA snapshot of challenges and solutions in cancer drug development and therapy.Clin Pharmacol Ther 95 341-6 4/1/2014
  • Grenade C, Phelps MA, Villalona-Calero MARace and ethnicity in cancer therapy: what have we learned?Clin Pharmacol Ther 95 403-12 4/1/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy NA novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Nanomedicine 10 393-400 2/1/2014
  • Kitzmiller JP, Phelps MA, Neidecker MV, Apseloff GEstablishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University.Adv Med Educ Pract 5 191-6 1/1/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MASensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.J Pharm Biomed Anal 88 262-8 1/1/2014
  • Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MFSite specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.Bioconjug Chem 24 1945-54 11/20/2013
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37 1195-9 10/1/2013
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum WPharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 54 1996-2002 9/1/2013
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52 705-12 8/1/2013
  • Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab TA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Invest New Drugs 31 685-95 6/1/2013
  • Zhou C, Zhang Y, Yu B, Phelps MA, Lee LJ, Lee RJComparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.Nanomedicine 9 504-13 5/1/2013
  • Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MAA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clin Cancer Res 19 1269-80 3/1/2013
  • Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy NMilatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Clin Cancer Res 19 347-56 1/15/2013
  • Kitzmiller JP, Sullivan DM, Phelps MA, Wang D, Sadee WCYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.Drug Metabol Drug Interact 28 59-63 1/1/2013
  • Kasai K, Nakashima H, Liu F, Kerr S, Wang J, Phelps M, Potter PM, Goins WB, Fernandez SA, Chiocca EAToxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs.Mol Ther Nucleic Acids 2 e113 1/1/2013
  • Spatola RA, Thangavelu M, Upadhyayula V, Lee S, Phelps MA, Chandler HLAnalysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells.Am J Vet Res 73 1987-95 12/1/2012
  • Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, Phelps MAPharmacokinetics and tissue disposition of lenalidomide in mice.AAPS J 14 872-82 12/1/2012
  • George M, Phelps MA, Kitzmiller JPAcetaminophen pediatric dose selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children.Clin Pediatr (Phila) 51 1030-1 11/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu